GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.

abstract：INTRODUCTION:Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications. AREA COVERED:This ...

journal_title：Expert opinion on investigational drugs

authors： Padrnos L,Mesa R

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat despite the availability of new drugs. This review aims to provide evidence to guide physicians in the choice of salvage therapy in certain subgroups of patients. AREAS COVERED:The review attempts to present evidence-based ...

journal_title：Expert opinion on investigational drugs

authors： Offidani M,Corvatta L,Morabito F,Gentile M,Musto P,Leoni P,Palumbo A

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. OBJECTIVE:Its use has been explored in different solid tumours. In this report ...

journal_title：Expert opinion on investigational drugs

authors： Abruzzese E,Iuliano F,Trawinska MM,Di Maio M

更新日期：2008-09-01 00:00:00

abstract：:ATP-gated P2X7 receptors (P2X7) make a unique family of extracellular ATP-activated plasma membrane ion channels expressed in haematopoietic and epithelial cells. They have been extensively studied in immune cells where their activation leads to the rapid release of pro-inflammatory cytokines and the initiation of the...

journal_title：Expert opinion on investigational drugs

authors： Roger S,Pelegrin P

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armoda...

journal_title：Expert opinion on investigational drugs

authors： Lankford DA

更新日期：2008-04-01 00:00:00

abstract：:Increasing evidence suggests an important role for autocrine/paracrine prolactin in breast and prostate cancers and other disease states. Prolactin production in these extrapituitary sites is not governed by dopamine agonists, a finding that has spurred the production of prolactin receptor antagonists. This review foc...

journal_title：Expert opinion on investigational drugs

authors： Walker AM

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is an age-associated, progressive, and irreversible fatal interstitial lung disease. Although many drugs have failed in clinical trials, these failures improved the understanding of the pathogenesis of IPF. Currently, there are two drugs approved for IPF that slow the pr...

journal_title：Expert opinion on investigational drugs

authors： Sato S,Yanagihara T,Kolb MRJ

更新日期：2019-01-01 00:00:00

abstract：:Recent landmark studies using hydroxy-methyl-glutaryl-Co-enzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins), specifically, pravastatin and simvastatin, have led to dramatic changes in medical practice. These clinical trials have demonstrated that clinicians can impact coronary morbidity and mortal...

journal_title：Expert opinion on investigational drugs

authors： Mellies M,McGovern M

更新日期：1997-01-01 00:00:00

abstract：INTRODUCTION:Psychostimulants are first-line treatments for attention-deficit/hyperactivity disorder (ADHD), but their tolerability profiles and individual response variability fuel a continuing search for alternative medications. The observation that nicotinic agents improve cognition has led pharmaceutical companies ...

journal_title：Expert opinion on investigational drugs

authors： Fleisher C,McGough J

更新日期：2014-08-01 00:00:00

abstract：:'Male factor' problems contribute to subfertility in a significant proportion of couples. In some instances, defective sperm production has qualitative and/or quantitative effects on the semen profile; in others, no obvious defects can be detected, yet spermatozoa are non-fertilising. Recent studies have revealed that...

journal_title：Expert opinion on investigational drugs

authors： Fraser LR

更新日期：1997-12-01 00:00:00

abstract：:Presentations at the William Harvey Research Conference on PDE Inhibitors described the molecular biology, biochemical regulation. pharmacology, and therapeutic utility of inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Most of the talks focused on PDE4 and PDE5. two members of the 11-member PDE family that...

journal_title：Expert opinion on investigational drugs

authors： O'Donnell

更新日期：2000-03-01 00:00:00

abstract：:The association of abnormalities in the cellular and humoral immune system with various autoimmune diseases provides the rationale for apheresis technologies. While plasmapheresis or plasma exchange is limited by its non-selective removal of all plasma components, modern apheresis techniques aim to provide more specif...

journal_title：Expert opinion on investigational drugs

authors： Braun N,Bosch T

更新日期：2000-09-01 00:00:00

abstract：:The discovery of new antibacterial drugs can be based either upon empirical screening methods or structure-based design. Empirical methods utilise both intact bacteria and isolated biochemical targets for high throughput screening of natural product or chemical libraries to detect inhibitor leads. Structure-based meth...

journal_title：Expert opinion on investigational drugs

authors： Chopra I

更新日期：1997-08-01 00:00:00

abstract：INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

journal_title：Expert opinion on investigational drugs

authors： Thanarajasingam U,Niewold TB

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however...

journal_title：Expert opinion on investigational drugs

authors： Gentile I,Zappulo E,Buonomo AR,Maraolo AE,Borgia G

更新日期：2015-01-01 00:00:00

abstract：:Innate immune mechanisms respond rapidly to bacterial infection. A key cellular component of the innate immune response is the neutrophil, whose cytoplasmic granules contain a variety of antimicrobial proteins and peptides. Among these is the bactericidal/permeability-increasing protein (BPI), a cationic 55 kDa protei...

journal_title：Expert opinion on investigational drugs

authors： Levy O

更新日期：2002-02-01 00:00:00

abstract：INTRODUCTION:Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of tho...

journal_title：Expert opinion on investigational drugs

authors： Martínez-Peinado N,Cortes-Serra N,Losada-Galvan I,Alonso-Vega C,Urbina JA,Rodríguez A,VandeBerg JL,Pinazo MJ,Gascon J,Alonso-Padilla J

更新日期：2020-09-01 00:00:00

abstract：:Telomerase is a holoenzyme responsible for the maintenance of telomeres, the protein-nucleic acid complexes at the ends of eukaryotic chromosomes that serve to maintain chromosomal stability and integrity. Telomerase activity is essential for the sustained proliferation of most immortal cells, including cancer cells. ...

journal_title：Expert opinion on investigational drugs

authors： Perry PJ,Arnold JR,Jenkins TC

更新日期：2001-12-01 00:00:00

abstract：INTRODUCTION:Minimal change disease (MCD) and Focal and segmental glomerulosclerosis (FSGS) are two of the major causes of nephrotic syndrome (NS) in children and adults. According to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, the treatment of adult primary MCD and FSGS should be based on immunosuppr...

journal_title：Expert opinion on investigational drugs

authors： Siligato R,Cernaro V,Nardi C,De Gregorio F,Gembillo G,Costantino G,Conti G,Buemi M,Santoro D

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Because of the central role of the mammalian target of rapamycin (mTOR) pathway in the control and distribution of signals essential for mRNA translation of mitogenic genes and generation of oncogenic proteins, effective targeting of mTOR remains a major goal in medical oncology. AREAS COVERED:This articl...

journal_title：Expert opinion on investigational drugs

authors： Nelson V,Altman JK,Platanias LC

更新日期：2013-06-01 00:00:00

abstract：INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

journal_title：Expert opinion on investigational drugs

authors： Folli F,Guardado Mendoza R

更新日期：2011-12-01 00:00:00

abstract：:PTI-821 is a long-acting formulation of oxycodone that is intended to deter abuse through its gel-cap technology. Produced by Pain Therapeutics in alliance with King Pharmaceuticals, PTI-821 is designed to provide strong pain relief with the intent of offering greater safety than is presently available from convention...

journal_title：Expert opinion on investigational drugs

authors： Webster LR

更新日期：2007-03-01 00:00:00

abstract：:There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolys...

journal_title：Expert opinion on investigational drugs

authors： Movsesian MA

更新日期：2000-05-01 00:00:00

abstract：:Considerable advances have been made on compounds that are active as inhibitors of HIV entry and fusion. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors in addition to fusion and attachment blockers. During the last 5 years, there has been an intense research activity from bo...

journal_title：Expert opinion on investigational drugs

authors： Citterio P,Rusconi S

更新日期：2007-01-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Contrasting with the broad activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) survival pathway in most cancer, activity of rapalogues appears to be restricted to a few tumor types. AREAS COVERED IN THIS REVIEW:The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resi...

journal_title：Expert opinion on investigational drugs

authors： Albert S,Serova M,Dreyer C,Sablin MP,Faivre S,Raymond E

更新日期：2010-08-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Hepatitis C virus (HCV) is the main agent of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma in the western world. It affects more than 170 million people worldwide. HCV treatment, based on the combination of Peg-interferon and ribavirin, is effective in about 50% of treated pati...

journal_title：Expert opinion on investigational drugs

authors： Gentile I,Carleo MA,Borgia F,Castaldo G,Borgia G

更新日期：2010-01-01 00:00:00

abstract：INTRODUCTION:In the last decade, concerns have been raised around the use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in chronic kidney disease (CKD) patients, especially when given at high doses. Moreover, treatment with ESA is expensive. AREAS COVERED:We searched PubMed for original articles, re...

journal_title：Expert opinion on investigational drugs

authors： Del Vecchio L,Locatelli F

更新日期：2018-07-01 00:00:00

abstract：:In most countries the last two decades have seen a very substantial rise in the prevalence of heart failure, and in a majority of patients hypertension is both an antecedent condition and a contributing cause. Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevent...

journal_title：Expert opinion on investigational drugs

authors： Funder JW

更新日期：2003-12-01 00:00:00

abstract：:Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

journal_title：Expert opinion on investigational drugs

authors： Fam AG

更新日期：2001-07-01 00:00:00

abstract：:Risperidone (Risperdal) is a benzisoxazole derivative with a high affinity for serotonin 5-HT2 and dopamine D2 receptors, and some affinity for alpha- adrenergic, histamine H1 and dopamine D1 receptors. It has no anticholinergic effects. Early studies demonstrated risperidone to be an effective medication for psychoti...

journal_title：Expert opinion on investigational drugs

authors： Keks NA,Culhane C

更新日期：1999-04-01 00:00:00